Patents by Inventor Robert C. Cuca

Robert C. Cuca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9789057
    Abstract: A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 ?g to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: October 17, 2017
    Assignee: Perrigo Pharma International Designated Activity Company
    Inventors: Thomas C. Riley, R. Saul Levinson, Robert C. Cuca, Elio Mariani
  • Publication number: 20150359743
    Abstract: The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.
    Type: Application
    Filed: May 27, 2015
    Publication date: December 17, 2015
    Inventors: Joseph M. Davis, Robert C. Cuca, Edward J. Beasley
  • Publication number: 20130172279
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: July 25, 2012
    Publication date: July 4, 2013
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
  • Publication number: 20130102548
    Abstract: A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 ?g to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.
    Type: Application
    Filed: July 23, 2012
    Publication date: April 25, 2013
    Applicant: DRUGTECH CORPORATION
    Inventors: Thomas C. Riley, R. Saul Levinson, Robert C. Cuca, Elio Mariani
  • Patent number: 8057433
    Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: November 15, 2011
    Assignee: DrugTech Corporation
    Inventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
  • Publication number: 20110276030
    Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
    Type: Application
    Filed: July 8, 2005
    Publication date: November 10, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
  • Publication number: 20110251141
    Abstract: A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
    Type: Application
    Filed: June 20, 2011
    Publication date: October 13, 2011
    Applicant: DRUGTECH CORPORATION
    Inventors: Jonathan Bortz, R. Saul Levinson, Mitchell Kirschner, Robert C. Cuca
  • Publication number: 20080287408
    Abstract: A pharmaceutical composition comprises at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to a vaginal mucosal surface, and comprises danazol in an amount of about 3% to about 30% by weight of the composition, wherein upon application of the composition to the vaginal mucosal surface the danazol is released over a period of about 1 to about 10 days. The composition is useful for intravaginal administration to treat a condition such as endometriosis for which danazol is indicated.
    Type: Application
    Filed: April 18, 2008
    Publication date: November 20, 2008
    Applicant: DRUGTECH CORPORATION
    Inventors: Daniel J. Thompson, Robert C. Cuca, Thomas C. Riley, JR., Jonathan David Bortz
  • Publication number: 20080097388
    Abstract: A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
    Type: Application
    Filed: July 8, 2005
    Publication date: April 24, 2008
    Applicants: DRUGTECH CORPORATION
    Inventors: Robert C. Cuca, Thomas C. Riley, R. Saul Levinson
  • Publication number: 20080003262
    Abstract: A method for treating non-infectious inflammatory vulvovaginitis comprises administering to a vulvovaginal surface a pharmaceutical composition that comprises clindamycin in an amount of about 125 mg to about 400 mg per unit dose of the composition; wherein the composition is bioadhesive to the vulvovaginal surface, and upon application of the composition to the vulvovaginal surface the clindamycin is released over a period of about 3 hours to about 14 days. A related method comprises administering to a vulvovaginal surface a pharmaceutical composition comprising clindamycin or a pharmaceutically acceptable salt or ester thereof, wherein the composition has at least one non-lipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. A pharmaceutical composition comprises (a) clindamycin or a pharmaceutically acceptable salt or ester thereof in a clindamycin equivalent amount of about 2.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 3, 2008
    Applicant: DrugTech Corporation
    Inventors: R. Saul Levinson, Robert C. Cuca, Jonathan Bortz
  • Publication number: 20020187205
    Abstract: Multi-vitamin and mineral supplements for administration to non-lactating women, which comprise specific regimens of vitamins and minerals tailored to meet the physiological needs of said women. Methods for optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods for formulating a multi-vitamin and mineral supplement that optimize the health of a woman and which comprise identifying life stages which correlate to specific nutritional requirements as a result of varying physiological conditions during a lifetime and selecting specific types and optimal amounts of vitamins and minerals for said life stages.
    Type: Application
    Filed: July 31, 2002
    Publication date: December 12, 2002
    Applicant: K-V Pharmaceutical Company
    Inventors: George N. Paradissis, R. Saul Levinson, Robert C. Cuca, Patrick Paul Vanek
  • Patent number: 6488956
    Abstract: Multi-vitamin and mineral supplements for administration to non-lactating women, which comprise specific regimens of vitamins and minerals tailored to meet the physiological needs of said women. Methods for optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods for formulating a multi-vitamin and mineral supplement that optimize the health of a woman and which comprise identifying life stages which correlate to specific nutritional requirements as a result of varying physiological conditions during a lifetime and selecting specific types and optimal amounts of vitamins and minerals for said life stages.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: December 3, 2002
    Assignee: Drugtech Corporation
    Inventors: George N. Paradissis, R. Saul Levinson, Robert C. Cuca, Patrick Paul Vanek
  • Patent number: 5869084
    Abstract: Multi-vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women, which comprise specific regimens of critical nutritional agents. The supplements are specifically tailored to meet nutritional requirements and maintain a woman's health during each stage of life.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 9, 1999
    Assignee: K-V Pharmaceuticals Co.
    Inventors: George N. Paradissis, R. Saul Levinson, Gary Heeter, Robert C. Cuca, Patrick Paul Vanek
  • Patent number: 5858391
    Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.
    Type: Grant
    Filed: May 28, 1997
    Date of Patent: January 12, 1999
    Assignee: KV Pharmaceutical Company
    Inventors: Robert C. Cuca, Keith S. Lienhop, Thomas Charles Riley, Jr., Mitchell I. Kirschner, R. Saul Levinson
  • Patent number: 5730997
    Abstract: A substantially tasteless liquid phramaceutical delivery system containing an active material and a high osmolarity aqueous system comprising (i) water; (ii) about 20% to about 45% by weight sugar derivative; (iii) about 10% to about 15% by weight hydrogenated maltose syrup; and (iv) about 0% to about 35% by weight polyhydroxy alcohol.
    Type: Grant
    Filed: September 11, 1996
    Date of Patent: March 24, 1998
    Assignee: KV Pharmaceutical Company
    Inventors: Keith S. Lienhop, Robert C. Cuca, Thomas Charles Riley, Jr., R. Saul Levinson
  • Patent number: 5670163
    Abstract: A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: September 23, 1997
    Assignee: KV Pharmaceuticals Company
    Inventors: Robert C. Cuca, Keith S. Lienhop, Thomas Charles Riley, Jr., Mitchell I. Kirschner, R. Saul Levinson
  • Patent number: 5554380
    Abstract: A solid or semi-solid bioadherent, orally ingestible drug delivery system containing a water-in-oil system having at least two phases, one phase comprises from about 25% to about 75% by volume of an internal hydrophilic phase and the other phase comprises from about 25% to about 75% by volume of an external hydrophobic phase and wherein the external hydrophobic phase is comprised of three components, a) an emulsifier, b) a glyceride ester and c) a wax material.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: September 10, 1996
    Assignee: KV Pharmaceutical Company
    Inventors: Robert C. Cuca, Keith S. Lienhop, Thomas C. Riley, Jr., R. Saul Levinson, Mitchell I. Kirschner
  • Patent number: 5494681
    Abstract: A substantially tasteless pharmaceutical delivery system, which comprises a) an active material; and b) a spatially oriented matrix comprising (i) a wax core material having a melting point within the range of about 50.degree. C. and about 200.degree. C.; and (ii) a regional hydrophobic polymer material and method for making the same.
    Type: Grant
    Filed: August 11, 1994
    Date of Patent: February 27, 1996
    Assignee: KV Pharmaceutical Company
    Inventors: Robert C. Cuca, Ronald S. Harland, Thomas C. Riley, Jr., Yury Lagoviyer, R. Saul Levinson
  • Patent number: 5002777
    Abstract: A concentrated suspension of calcium carbonate particles in a liquid carrier that is compatible with a capsule shell material. The suspension is pourable and pumpable and may be used to provide antacid capsules.
    Type: Grant
    Filed: November 9, 1986
    Date of Patent: March 26, 1991
    Assignee: Norcliff Thayer Inc.
    Inventor: Robert C. Cuca
  • Patent number: 4656028
    Abstract: A concentrated suspension of calcium carbonate particles in a liquid carrier that is compatible with a capsule shell material. The suspension is pourable and pumpable and may be used to provide antacid capsules.
    Type: Grant
    Filed: June 24, 1986
    Date of Patent: April 7, 1987
    Assignee: Norcliff Thayer Inc.
    Inventor: Robert C. Cuca